[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 509
2. Mani T, Liu D, Zhou D, Li L, Knabe WE, Wang F, Oh K, Meroueh SO: Probing binding and cellular activity of pyrrolidinone and piperidinone small molecules targeting the urokinase receptor. ChemMedChem; 2013 Dec;8(12):1963-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In cells, pyrazole-based compounds showed significant inhibition of breast adenocarcinoma (MDA-MB-231) and pancreatic ductal adenocarcinoma (PDAC) cell proliferation, but piperidinone-containing compounds exhibited no cytotoxicity even at concentrations of 100 μM.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
  • [Cites] Cell Mol Life Sci. 2000 Jan 20;57(1):25-40 [10949579.001]
  • [Cites] Bioorg Med Chem. 2013 Apr 1;21(7):2145-55 [23411397.001]
  • [Cites] Am J Pathol. 2001 Sep;159(3):971-82 [11549590.001]
  • [Cites] Mol Biol Cell. 2001 Oct;12(10):2975-86 [11598185.001]
  • [Cites] Cancer Cell. 2002 Jun;1(5):445-57 [12124174.001]
  • [Cites] Curr Mol Med. 2003 Nov;3(7):659-71 [14601640.001]
  • [Cites] J Biol Chem. 2003 Nov 21;278(47):46692-8 [12963722.001]
  • [Cites] Adv Cancer Res. 1985;44:139-266 [2930999.001]
  • [Cites] J Biol Chem. 1986 Dec 5;261(34):15819-22 [3023326.001]
  • [Cites] J Cell Biol. 1987 Apr;104(4):801-4 [3031083.001]
  • [Cites] Cancer Res. 1987 Jun 15;47(12):3239-45 [2438036.001]
  • [Cites] Br J Cancer. 1987 Sep;56(3):279-85 [3663476.001]
  • [Cites] J Biol Chem. 1989 Feb 5;264(4):2185-8 [2521625.001]
  • [Cites] J Biol Chem. 1991 Jul 5;266(19):12752-8 [1829461.001]
  • [Cites] Int J Cancer. 1996 Jul 29;67(3):423-9 [8707419.001]
  • [Cites] Cancer. 1997 Oct 15;80(8 Suppl):1529-37 [9362419.001]
  • [Cites] Nat Genet. 1997 Dec;17(4):439-44 [9398846.001]
  • [Cites] Bioorg Med Chem Lett. 1998 Oct 6;8(19):2787-92 [9873623.001]
  • [Cites] J Cell Biol. 2005 Jan 31;168(3):501-11 [15684035.001]
  • [Cites] Thromb Haemost. 2005 Apr;93(4):647-54 [15841308.001]
  • [Cites] EMBO J. 2005 May 18;24(10):1787-97 [15889147.001]
  • [Cites] Science. 2006 Feb 3;311(5761):656-9 [16456079.001]
  • [Cites] Int J Oncol. 2006 Apr;28(4):831-9 [16525631.001]
  • [Cites] Proteins. 2006 Nov 15;65(3):712-25 [16981200.001]
  • [Cites] J Biol Chem. 2007 May 4;282(18):13561-72 [17355965.001]
  • [Cites] Int J Cancer. 2007 Nov 15;121(10):2307-16 [17657740.001]
  • [Cites] J Am Chem Soc. 2007 Dec 19;129(50):15668-76 [18041838.001]
  • [Cites] J Pathol. 2008 Feb;214(3):283-93 [18095256.001]
  • [Cites] Nat Struct Mol Biol. 2008 Apr;15(4):422-3 [18376415.001]
  • [Cites] J Cell Biochem. 2009 Nov 1;108(4):916-25 [19693769.001]
  • [Cites] J Comput Chem. 2010 Jan 30;31(2):455-61 [19499576.001]
  • [Cites] Int J Oncol. 2010 May;36(5):1155-63 [20372789.001]
  • [Cites] Cancer Res. 2010 Jul 15;70(14):5649-69 [20610625.001]
  • [Cites] BMC Cancer. 2010;10:647 [21106094.001]
  • [Cites] Cell. 2011 Mar 4;144(5):646-74 [21376230.001]
  • [Cites] Curr Pharm Des. 2011;17(19):1874-89 [21711237.001]
  • [Cites] J Biol Chem. 2011 Sep 23;286(38):33544-56 [21799009.001]
  • [Cites] J Med Chem. 2011 Oct 27;54(20):7193-205 [21851064.001]
  • [Cites] ACS Chem Biol. 2011 Nov 18;6(11):1232-43 [21875078.001]
  • [Cites] J Biol Chem. 2011 Dec 16;286(50):43515-26 [22025616.001]
  • [Cites] J Mol Biol. 2012 Mar 9;416(5):629-41 [22285761.001]
  • [Cites] Bioorg Med Chem. 2012 Aug 1;20(15):4760-73 [22771232.001]
  • [Cites] J Biol Chem. 2012 Oct 5;287(41):34304-15 [22896701.001]
  • [Cites] Mol Biol Cell. 2001 May;12(5):1467-79 [11359936.001]
  • (PMID = 24115356.001).
  • [ISSN] 1860-7187
  • [Journal-full-title] ChemMedChem
  • [ISO-abbreviation] ChemMedChem
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA082709; United States / NCI NIH HHS / CA / R01 CA135380; United States / NCI NIH HHS / CA / CA135380
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Piperidines; 0 / Pyrrolidinones; 0 / Receptors, Urokinase Plasminogen Activator; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3
  • [Other-IDs] NLM/ NIHMS534207; NLM/ PMC4058332
  • [Keywords] NOTNLM ; cancer / inhibitors / invasion / metastasis / protein-protein interaction / small molecules / uPAR / urokinase / urokinase receptors
  •  go-up   go-down


3. Schuller HM, Al-Wadei HA: Neurotransmitter receptors as central regulators of pancreatic cancer. Future Oncol; 2010 Feb;6(2):221-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pancreatic ductal adenocarcinoma (PDAC) has a near 100% mortality because it is generally detected at an advanced stage and responds poorly to existing therapeutics.
  • Accordingly, PDAC intervention strategies should include the diagnosis of unphysiological neurotransmitter levels and aim to restore any imbalance in stimulatory and inhibitory neurotransmitters.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2006 Oct 1;119(7):1547-52 [16671086.001]
  • [Cites] Nat Med. 2006 Aug;12(8):939-44 [16862152.001]
  • [Cites] Life Sci. 2007 May 30;80(24-25):2274-80 [17459420.001]
  • [Cites] Toxicol Appl Pharmacol. 2007 Jun 15;221(3):261-7 [17498763.001]
  • [Cites] Cancer Res. 2007 Oct 15;67(20):9704-12 [17942900.001]
  • [Cites] Cancer. 2008 Feb 15;112(4):767-78 [18098271.001]
  • [Cites] Oncologist. 2008 May;13(5):562-76 [18515741.001]
  • [Cites] Anticancer Drugs. 2008 Aug;19(7):655-71 [18594207.001]
  • [Cites] Int J Oncol. 2008 Aug;33(2):415-9 [18636164.001]
  • [Cites] Br J Pharmacol. 2008 Aug;154(8):1558-71 [18500366.001]
  • [Cites] J Cell Biochem. 2008 Sep 1;105(1):53-60 [18452159.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2008 Oct 12;363(1507):3159-68 [18640919.001]
  • [Cites] Nat Rev Cancer. 2009 Mar;9(3):195-205 [19194381.001]
  • [Cites] Carcinogenesis. 2009 Mar;30(3):506-11 [19131543.001]
  • [Cites] Pancreas. 2009 May;38(4):416-21 [19169171.001]
  • [Cites] Anticancer Drugs. 2009 Jul;20(6):477-82 [19387337.001]
  • [Cites] Nat Rev Gastroenterol Hepatol. 2009 Jul;6(7):412-22 [19506583.001]
  • [Cites] J Pathol. 2009 Aug;218(4):437-45 [19274673.001]
  • [Cites] Curr Opin Pharmacol. 2009 Aug;9(4):411-8 [19589727.001]
  • [Cites] Teratog Carcinog Mutagen. 2001;21(1):7-25 [11135318.001]
  • [Cites] Psychooncology. 2001 Jan-Feb;10(1):19-28 [11180574.001]
  • [Cites] Carcinogenesis. 2001 Mar;22(3):473-9 [11238189.001]
  • [Cites] Oncogene. 2001 Mar 26;20(13):1532-9 [11313899.001]
  • [Cites] J Neurochem. 2001 Sep;78(6):1367-78 [11579145.001]
  • [Cites] Neurosci Lett. 2002 Sep 13;330(1):9-12 [12213622.001]
  • [Cites] J Cancer Res Clin Oncol. 2002 Oct;128(10):525-32 [12384795.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6467-9 [12438237.001]
  • [Cites] J Neurosci. 2002 Dec 1;22(23):10172-81 [12451118.001]
  • [Cites] Ann N Y Acad Sci. 2002 Dec;978:405-12 [12582069.001]
  • [Cites] Breast Cancer Res Treat. 2003 Jul;80(1):63-70 [12889599.001]
  • [Cites] Clin Cancer Res. 2004 May 15;10(10):3327-32 [15161686.001]
  • [Cites] Mol Cancer. 2003 Jan 7;2:10 [12575899.001]
  • [Cites] Cancer Res. 1988 Dec 1;48(23):6912-7 [3180100.001]
  • [Cites] Biochem Pharmacol. 1989 Oct 15;38(20):3439-42 [2573356.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 May;87(9):3294-8 [2159143.001]
  • [Cites] Scand J Clin Lab Invest Suppl. 1990;201:25-43 [1978755.001]
  • [Cites] J Neurosci. 1992 Jul;12(7):2765-84 [1613557.001]
  • [Cites] Cancer Res. 1993 Jun 1;53(11):2498-501 [8495411.001]
  • [Cites] Prog Brain Res. 1996;109:125-37 [9009699.001]
  • [Cites] Endocrinology. 1997 Jun;138(6):2601-9 [9165054.001]
  • [Cites] Biochem Pharmacol. 1998 May 1;55(9):1377-84 [10076528.001]
  • [Cites] Cancer Res. 1999 Sep 15;59(18):4510-5 [10493497.001]
  • [Cites] Biol Psychiatry. 2005 Jan 1;57(1):44-8 [15607299.001]
  • [Cites] J Cell Biochem. 2005 Jul 1;95(4):649-56 [15849724.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 Oct;131(10):639-48 [16091975.001]
  • [Cites] Pancreas. 2005 Nov;31(4):301-16 [16258363.001]
  • [Cites] Mol Pharmacol. 2006 Feb;69(2):618-28 [16269536.001]
  • [Cites] Auton Neurosci. 2006 Jan 30;124(1-2):1-8 [16338174.001]
  • [Cites] Int J Cancer. 2006 Jun 1;118(11):2744-9 [16381019.001]
  • [Cites] Cancer Biol Ther. 2006 May;5(5):511-7 [16582591.001]
  • [Cites] Pancreas. 2006 Jul;33(1):53-62 [16804413.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10357-64 [17079456.001]
  • (PMID = 20146581.001).
  • [ISSN] 1744-8301
  • [Journal-full-title] Future oncology (London, England)
  • [ISO-abbreviation] Future Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA042829; United States / NCI NIH HHS / CA / CA042829-14; United States / NCI NIH HHS / CA / CA042829-15A2; United States / NCI NIH HHS / CA / R01 CA042829-14; United States / NCI NIH HHS / CA / R01 CA130888; United States / NCI NIH HHS / CA / CA130888-01A2; United States / NCI NIH HHS / CA / R01 CA130888-01A2; United States / NCI NIH HHS / CA / R01 CA042829-15A2
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neurotransmitter Agents; 0 / Receptors, Neurotransmitter
  • [Number-of-references] 55
  • [Other-IDs] NLM/ NIHMS180625; NLM/ PMC2832917
  •  go-up   go-down


Advertisement
4. Huang D, Xu W, Xu X, Zhang X, Zhou R, Chen P: EMT influences the expression of CK19 in pleural effusion-derived lung cancer cells and their invasion and metastasis. Oncol Lett; 2016 Dec;12(6):5052-5058
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lung cancer is the most common cancer after breast and colon cancer, with high rates of mortality, worldwide.
  • Even though a number of markers have been suggested for the diagnosis of lung cancer and monitoring of disease progression, there is no clear way of assessing the invasion, epithelial-mesenchymal transition (EMT) and metastasizing capability of the primary tumor cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Respir J. 1996 Jan;9(1):17-23 [8834328.001]
  • [Cites] Thorax. 2008 Jan;63(1):35-41 [17573438.001]
  • [Cites] Pathology. 2010 Apr;42(3):224-8 [20350214.001]
  • [Cites] Trends Cell Biol. 2001 Nov;11(11):S44-51 [11684442.001]
  • [Cites] Pathology. 2007 Jun;39(3):305-18 [17558857.001]
  • [Cites] Mol Cancer Res. 2012 Aug;10(8):1032-8 [22767590.001]
  • [Cites] Dev Dyn. 2005 Jul;233(3):706-20 [15937929.001]
  • [Cites] Br J Cancer. 1999 Nov;81(6):1059-65 [10576665.001]
  • [Cites] Clin Cancer Res. 2015 May 15;21(10):2244-55 [25979931.001]
  • [Cites] Curr Opin Genet Dev. 2002 Feb;12(1):22-9 [11790550.001]
  • [Cites] Pol Arch Med Wewn. 2009 Jan-Feb;119(1-2):33-7 [19341176.001]
  • [Cites] Clin Chest Med. 2002 Mar;23(1):65-81, viii [11901921.001]
  • [Cites] J Thorac Oncol. 2006 Sep;1(7):611-21 [17409927.001]
  • [Cites] Ecancermedicalscience. 2014 Jan 30;8:394 [24567753.001]
  • [Cites] Oncol Lett. 2013 Mar;5(3):1043-1047 [23426647.001]
  • [Cites] Cancer Cytopathol. 2013 Sep;121(9):483-8 [23408492.001]
  • [Cites] Respiration. 2000;67(1):24-9 [10705258.001]
  • [Cites] Pathol Res Pract. 1999;195(6):379-89 [10399178.001]
  • [Cites] J Cell Sci. 2011 Oct 1;124(Pt 19):3189-97 [21940791.001]
  • [Cites] Cell Mol Biol Lett. 2007 Sep;12 (3):457-72 [17457524.001]
  • [Cites] Crit Rev Oncog. 1999;10(4):303-60 [10654929.001]
  • [Cites] Curr Opin Pulm Med. 2014 Jul;20(4):317-23 [24852329.001]
  • [Cites] Cancers (Basel). 2012 Dec 21;5(1):1-11 [24216695.001]
  • [Cites] Eur J Pharmacol. 2015 May 5;754:82-91 [25725115.001]
  • [Cites] CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90 [21296855.001]
  • [Cites] Curr Opin Oncol. 2005 Jan;17(1):49-54 [15608513.001]
  • [Cites] BMC Cancer. 2013 Jul 23;13:354 [23879483.001]
  • [Cites] Cancer Metastasis Rev. 2006 Sep;25(3):435-57 [16951986.001]
  • (PMID = 28105212.001).
  • [ISSN] 1792-1074
  • [Journal-full-title] Oncology letters
  • [ISO-abbreviation] Oncol Lett
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Keywords] NOTNLM ; CYFRA21-1 / adenocarcinoma / cytokeratin 19 / endothelial-mesenchymal transition / metastasis / pleural effusion / small cell lung carcinoma / squamous cell carcinoma / transforming growth factor-β1
  •  go-up   go-down


5. Arthur AE, Delk A, Demark-Wahnefried W, Christein JD, Contreras C, Posey JA 3rd, Vickers S, Oster R, Rogers LQ: Pancreatic cancer survivors' preferences, barriers, and facilitators related to physical activity and diet interventions. J Cancer Surviv; 2016 Dec;10(6):981-989
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Seventy-one survivors treated for resectable pancreatic adenocarcinoma from October 2011 to August 2014 were identified through an institutional cancer registry and contacted via telephone.
  • A telephone survey was conducted to query survivors' level of interest in, preferences for, and perceived barriers and facilitators to participating in an exercise and dietary intervention program shortly after disease diagnosis.
  • CONCLUSIONS: Most pancreatic cancer patients are interested in exercise and diet interventions shortly after diagnosis; however, some barriers to program participation exist.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Exercise and Physical Fitness.
  • MedlinePlus Health Information. consumer health - Exercise for Seniors.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Sports Med. 2016 Mar;50(6):325-38 [25966911.001]
  • [Cites] Psychooncology. 2016 Feb;25(2):150-7 [26123474.001]
  • [Cites] J Phys Act Health. 2015 Jun;12(6):823-33 [25155470.001]
  • [Cites] Oncol Hematol Rev. 2012;8(2):81-88 [23667857.001]
  • [Cites] Support Care Cancer. 2011 Nov;19(11):1729-34 [20967470.001]
  • [Cites] Breast Cancer Res Treat. 2015 Jan;149(2):331-42 [25555831.001]
  • [Cites] BMC Cancer. 2012 Sep 06;12:390 [22950826.001]
  • [Cites] JMIR Mhealth Uhealth. 2015 Sep 15;3(3):e88 [26373696.001]
  • [Cites] J Nutr. 2007 Jan;137(1 Suppl):243S-248S [17182834.001]
  • [Cites] Pancreatology. 2009;9(6):729-37 [20090394.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2011 Jan;20(1):123-33 [21051654.001]
  • [Cites] World J Gastroenterol. 2014 Jul 28;20(28):9361-73 [25071331.001]
  • [Cites] Br J Surg. 2005 Apr;92(4):471-7 [15672431.001]
  • [Cites] Crit Rev Oncol Hematol. 2000 Jun;34(3):137-68 [10838261.001]
  • [Cites] Hepatogastroenterology. 2005 May-Jun;52(63):927-32 [15966234.001]
  • [Cites] Semin Oncol Nurs. 2009 Feb;25(1):76-92 [19217507.001]
  • [Cites] Digestion. 2006;74(2):118-25 [17191029.001]
  • [Cites] Int J Gastrointest Cancer. 2006;37(2-3):65-73 [17827524.001]
  • [Cites] Psychooncology. 2009 Apr;18(4):412-21 [19241491.001]
  • [Cites] J Med Internet Res. 2007 Jul 12;9(3):e20 [17627929.001]
  • [Cites] Am J Prev Med. 2014 Nov;47(5):613-6 [25070271.001]
  • [Cites] Support Care Cancer. 2008 Dec;16(12):1353-60 [18386075.001]
  • [Cites] J Cancer Surviv. 2011 Sep;5(3):263-70 [21505861.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):748-55 [7884435.001]
  • [Cites] Support Care Cancer. 2009 Apr;17(4):349-57 [18543006.001]
  • [Cites] Int J Cancer. 2009 Jun 15;124(12):2960-5 [19330830.001]
  • [Cites] J Cancer Surviv. 2013 Sep;7(3):355-68 [23532799.001]
  • [Cites] Health Expect. 2015 Dec;18(6):3088-98 [25382413.001]
  • [Cites] J Cancer Surviv. 2015 Dec;9(4):660-82 [25757733.001]
  • [Cites] Head Neck. 2009 Aug;31(8):994-1005 [19340875.001]
  • [Cites] J Am Coll Surg. 2012 Apr;214(4):463-75; discussion 475-7 [22321518.001]
  • [Cites] Eur J Cardiovasc Nurs. 2015 Apr;14(2):153-61 [24463729.001]
  • [Cites] J Cancer Surviv. 2010 Jun;4(2):87-100 [20052559.001]
  • [Cites] Psychooncology. 2013 Apr;22(4):829-36 [22573338.001]
  • [Cites] Pancreas. 2015 Jul;44(5):750-5 [25872172.001]
  • [Cites] Cancer Pract. 2002 Jul-Aug;10(4):208-15 [12100105.001]
  • [Cites] BMC Public Health. 2014 Jul 21;14:738 [25047900.001]
  • [Cites] Int J Clin Oncol. 2013 Oct;18(5):839-46 [22996141.001]
  • (PMID = 27138993.001).
  • [ISSN] 1932-2267
  • [Journal-full-title] Journal of cancer survivorship : research and practice
  • [ISO-abbreviation] J Cancer Surviv
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA013148; United States / NIDDK NIH HHS / DK / P30 DK079626; United States / NCI NIH HHS / CA / R25 CA047888
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Diet / Exercise / Health behavior / Intervention / Pancreatic cancer / Preferences / Quality of life / Survivorship / Technology-based
  •  go-up   go-down


6. Aleck K, Hallman K, Quigley M, Lloyd V, Szmyd M, Ruskin D, Bedgood T, Dinda S: Effects of Atrial Natriuretic Peptide on p53 and Estrogen Receptor in Breast Cancer Cells. Biores Open Access; 2017;6(1):141-150
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of Atrial Natriuretic Peptide on p53 and Estrogen Receptor in Breast Cancer Cells.
  • Previous research indicates ANP treatment significantly decreases the proliferation of human prostate cancer cells, pancreatic adenocarcinoma, and breast cancer cells.
  • Minimal studies have been conducted with regard to ANP regulating tumor suppressor genes and steroid hormone receptors in breast cancer cells.
  • Our study analyzed the effects of ANP in combination with 17β-estradiol (E<sub>2</sub>) and antiestrogen treatments on p53 and ERα levels in T-47D breast cancer cells.
  • Our studies indicate that ANP has potential as a therapeutic breast cancer treatment and should inspire further studies on the molecular mechanism of ANP in T-47D breast cancer cells.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Syst Biol Reprod Med. 2011 Dec;57(6):279-87 [22077725.001]
  • [Cites] Horm Mol Biol Clin Investig. 2010 Aug 1;2(1):211-7 [25961194.001]
  • [Cites] Cancers (Basel). 2011 Mar 08;3(1):1182-94 [24212659.001]
  • [Cites] Oncogene. 1997 Aug 18;15(8):991-5 [9285694.001]
  • [Cites] Mol Cancer Res. 2010 Mar;8(3):343-52 [20215421.001]
  • [Cites] Anticancer Res. 2007 Nov-Dec;27(6B):3813-8 [18225537.001]
  • [Cites] Endocr Relat Cancer. 2013 May 30;20(3):R113-25 [23533248.001]
  • [Cites] Anticancer Res. 2011 Feb;31(2):395-402 [21378317.001]
  • [Cites] Indian J Surg. 2015 Apr;77(2):141-6 [26139969.001]
  • [Cites] Oncogene. 1999 Jan 28;18(4):1067-72 [10023683.001]
  • [Cites] Nature. 1989 Dec 7;342(6250):705-8 [2531845.001]
  • [Cites] Curr Pharm Des. 2010;16(9):1159-66 [20030620.001]
  • [Cites] CA Cancer J Clin. 2011 Nov-Dec;61(6):409-18 [21969133.001]
  • [Cites] J Steroid Biochem Mol Biol. 2001 May;77(2-3):135-41 [11377979.001]
  • [Cites] J Steroid Biochem Mol Biol. 2014 Jan;139:45-53 [24121066.001]
  • [Cites] Cancer. 2008 May 15;112(10):2130-42 [18383519.001]
  • [Cites] Breast Cancer Res Treat. 2014 Feb;144(1):11-9 [24487689.001]
  • [Cites] Oncogene. 2002 Jan 24;21(5):761-8 [11850804.001]
  • [Cites] Regul Pept. 2012 Nov 10;179(1-3):55-60 [22975659.001]
  • [Cites] Biochim Biophys Acta. 2012 Jun;1822(6):1004-18 [22387884.001]
  • [Cites] Anticancer Res. 2009 Apr;29(4):971-5 [19414334.001]
  • [Cites] Pharmacol Rep. 2017 Aug;69(4):798-805 [28591668.001]
  • [Cites] Eur J Clin Invest. 2005 Jan;35(1):60-9 [15638821.001]
  • [Cites] Anticancer Res. 2006 Nov-Dec;26(6B):4143-8 [17201125.001]
  • [Cites] J Biol Chem. 1995 Dec 1;270(48):28507-10 [7499360.001]
  • [Cites] Mol Cell Biochem. 1997 Oct;175(1-2):81-9 [9350037.001]
  • (PMID = 29098120.001).
  • [ISSN] 2164-7844
  • [Journal-full-title] BioResearch open access
  • [ISO-abbreviation] Biores Open Access
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; NPR-A / antiestrogens / breast cancer / estrogen receptor / p53 / tumor suppressors
  •  go-up   go-down


7. Ponti G, Luppi G, Losi L, Giannetti A, Seidenari S: Leser-Trélat syndrome in patients affected by six multiple metachronous primitive cancers. J Hematol Oncol; 2010;3:2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Usually, the sign of Leser-Trélat is associated with adenocarcinoma, most frequently of the colon, breast, or stomach, but also of the lung, kidney, liver, and pancreas.
  • Herein, we present a case that we believe is the first report of the sign of Leser-Trélat in association with occult gastric adenocarcinoma and the anamnestic oncologic history of five other multiple primitive cancers.
  • [MeSH-major] Adenocarcinoma / diagnosis. Intestinal Neoplasms / diagnosis. Neoplasms, Second Primary / diagnosis. Neoplastic Syndromes, Hereditary / diagnosis. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Aged, 80 and over. Humans. Keratosis, Seborrheic / complications. Keratosis, Seborrheic / diagnosis. Male

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Acad Dermatol. 1992 Jun;26(6):947-50 [1535080.001]
  • [Cites] J Med Genet. 2005 Nov;42(11):801-10 [15958502.001]
  • [Cites] Lancet Oncol. 2005 Dec;6(12):980-7 [16321766.001]
  • [Cites] Lancet Oncol. 2008 May;9(5):462-72 [18452857.001]
  • [Cites] Clin Exp Dermatol. 1988 May;13(3):177-9 [2977576.001]
  • [Cites] Acta Derm Venereol. 1991;71(2):166-9 [1675530.001]
  • [Cites] J Am Acad Dermatol. 2000 Aug;43(2 Pt 2):386-90 [10901731.001]
  • [Cites] N Engl J Med. 1987 Dec 17;317(25):1582-7 [2825016.001]
  • [Cites] Aust Fam Physician. 2009 Jul;38(7):498-505 [19575068.001]
  • (PMID = 20064244.001).
  • [ISSN] 1756-8722
  • [Journal-full-title] Journal of hematology & oncology
  • [ISO-abbreviation] J Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2820021
  •  go-up   go-down


8. Chay WY, Chew SH, Ong WS, Busmanis I, Li X, Thung S, Ngo L, Lim SL, Lim YK, Chia YN, Koh E, Pang C, Soh LT, Wang J, Ho TH, Tay SK, Lim-Tan SK, Lim KH, Chia JW, Goh LK: HER2 amplification and clinicopathological characteristics in a large Asian cohort of rare mucinous ovarian cancer. PLoS One; 2013;8(4):e61565
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of a total of 133 cases, the median age at diagnosis was 48.3 years (range, 15.8-89.0 years), comparatively younger than western cohorts.
  • 24% were noted to have a significant family history of malignancy of which breast and gastrointestinal cancers the most prominent.
  • Majority of the patients (80%) had stage I disease at diagnosis.
  • [MeSH-major] Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / pathology. Asian Continental Ancestry Group / genetics. Gene Amplification. Ovarian Neoplasms / genetics. Ovarian Neoplasms / pathology. Receptor, ErbB-2 / genetics


9. Wachter DL, Rauh C, Wenkel E, Fasching PA, Beckmann MW, Hartmann A: [Sebaceous breast carcinoma: report of a rare histological special subtype]. Pathologe; 2014 Feb;35(1):72-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Sebaceous breast carcinoma: report of a rare histological special subtype].
  • We report on a case of sebaceous carcinoma of the breast as a rare histological special subtype of breast cancer.
  • [MeSH-major] Adenocarcinoma, Sebaceous / pathology. Breast Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology. Muir-Torre Syndrome / pathology. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Biopsy, Needle. Breast / pathology. Diagnosis, Differential. Female. Humans. Mammography. Middle Aged. Neoplasms, Hormone-Dependent / diagnosis. Neoplasms, Hormone-Dependent / pathology. Prognosis. Receptor, ErbB-2 / analysis. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Ultrasonography, Mammary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Clin Exp Dermatol. 2009 Mar;34(2):264-6 [19187311.001]
  • [Cites] Geburtshilfe Frauenheilkd. 2011 Dec;71(12):1056-1066 [25253900.001]
  • [Cites] AJR Am J Roentgenol. 2000 Feb;174(2):541-2 [10658739.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1977 Oct 7;375(4):345-53 [199989.001]
  • [Cites] Virchows Arch. 2006 Oct;449(4):484-8 [16944238.001]
  • [Cites] Lancet Oncol. 2005 Dec;6(12):980-7 [16321766.001]
  • [Cites] Pathologe. 2010 Oct;31(6):489-96 [20960199.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):338-43 [11859205.001]
  • [Cites] Arch Pathol Lab Med. 1986 Nov;110(11):1045-53 [3022669.001]
  • [Cites] Virchows Arch. 2001 May;438(5):505-8 [11407480.001]
  • [Cites] Histopathology. 2010 Jan;56(1):133-47 [20055911.001]
  • (PMID = 24414613.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


10. Patil S, Chamberlain RS: Neoplasms associated with germline and somatic NF1 gene mutations. Oncologist; 2012;17(1):101-16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition to germline NF1 mutations, alteration of the somatic NF1 gene is associated with sporadic malignancies such as adenocarcinoma of the colon, myelodysplastic syndrome, and anaplastic astrocytoma.
  • An International Consensus Meeting to address and recommend best practices for screening, diagnosis, management, and follow-up of malignancies associated with NF1 is needed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gut. 2005 Aug;54(8):1129-35 [15840687.001]
  • [Cites] Neurology. 2005 Jul 26;65(2):205-11 [16043787.001]
  • [Cites] Am J Surg Pathol. 2005 Sep;29(9):1170-6 [16096406.001]
  • [Cites] Curr Opin Neurol. 2005 Oct;18(5):604-10 [16155448.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8422-30 [16293873.001]
  • [Cites] Radiology. 2005 Dec;237(3):967-72 [16237144.001]
  • [Cites] Neurosurgery. 2006 Jan;58(1):1-16; discussion 1-16 [16385324.001]
  • [Cites] Curr Opin Ophthalmol. 2006 Feb;17(1):7-11 [16436918.001]
  • [Cites] Clin Genet. 2006 Jul;70(1):1-13 [16813595.001]
  • [Cites] Biochem Pharmacol. 2006 Nov 30;72(11):1485-92 [16797490.001]
  • [Cites] Radiographics. 2007 Jan-Feb;27(1):237-57 [17235010.001]
  • [Cites] Cancer. 2007 Apr 1;109(7):1406-12 [17330850.001]
  • [Cites] Ann Neurol. 2007 Mar;61(3):189-98 [17387725.001]
  • [Cites] World J Gastroenterol. 2007 May 14;13(18):2629-32 [17552016.001]
  • [Cites] World J Gastroenterol. 2007 May 21;13(19):2761-3 [17569151.001]
  • [Cites] J Med Genet. 2007 Aug;44(8):481-4 [17369502.001]
  • [Cites] Neurosurgery. 2007 Oct;61(4):762-6; discussion 766-7 [17986937.001]
  • [Cites] Neurosurg Focus. 2007;23(5):E2 [18004964.001]
  • [Cites] Expert Rev Anticancer Ther. 2007 Nov;7(11):1591-610 [18020927.001]
  • [Cites] Ann Oncol. 2008 Feb;19(2):390-4 [17932395.001]
  • [Cites] J Neuropathol Exp Neurol. 2008 Mar;67(3):240-9 [18344915.001]
  • [Cites] J Neurooncol. 2008 May;88(1):87-96 [18246407.001]
  • [Cites] Neoplasia. 2008 Jul;10(7):680-6, 2 p following 686 [18592002.001]
  • [Cites] Clin Cancer Res. 2008 Jul 15;14(14):4550-5 [18628470.001]
  • [Cites] Rev Gastroenterol Mex. 2008 Jan-Mar;73(1):33-5 [18792672.001]
  • [Cites] Glia. 2008 Nov 1;56(14):1590-605 [18803326.001]
  • [Cites] Cancer. 2008 Oct 15;113(8):2020-8 [18780317.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1069-75 [18948947.001]
  • [Cites] J Med Genet. 2008 Nov;45(11):695-703 [18550698.001]
  • [Cites] Neoplasia. 2008 Dec;10(12):1362-72, following 1372 [19048115.001]
  • [Cites] Am J Gastroenterol. 2009 Mar;104(3):797-9 [19223891.001]
  • [Cites] Curr Neurol Neurosci Rep. 2009 May;9(3):247-53 [19348714.001]
  • [Cites] Clin Gastroenterol Hepatol. 2009 May;7(5):A28 [18926936.001]
  • [Cites] Lancet Oncol. 2009 May;10(5):508-15 [19410195.001]
  • [Cites] J Neurol Sci. 2009 Jun 15;281(1-2):20-3 [19345380.001]
  • [Cites] J Clin Oncol. 2009 Sep 1;27(25):4162-8 [19636009.001]
  • [Cites] Pediatr Blood Cancer. 2009 Dec 15;53(7):1231-7 [19621457.001]
  • [Cites] Leukemia. 1989 Apr;3(4):247-56 [2564452.001]
  • [Cites] Surv Ophthalmol. 1989 Mar-Apr;33(5):373-9 [2497540.001]
  • [Cites] Neurosurgery. 1989 Dec;25(6):959-64 [2513523.001]
  • [Cites] J Clin Gastroenterol. 1990 Feb;12(1):118-9 [2105991.001]
  • [Cites] Cancer. 1990 Apr 1;65(7):1591-5 [1968779.001]
  • [Cites] Neurofibromatosis. 1988;1(3):179-81 [3152466.001]
  • [Cites] Neurofibromatosis. 1989;2(3):152-65 [2517529.001]
  • [Cites] Cancer. 1990 Sep 15;66(6):1253-65 [2119249.001]
  • [Cites] Acta Oncol. 1991;30(4):477-83 [1854505.001]
  • [Cites] J Am Coll Surg. 2009 Dec;209(6):727-32 [19959041.001]
  • [Cites] J Gastrointest Surg. 2010 Jan;14(1):186-94 [19495890.001]
  • [Cites] JOP. 2010;11(1):64-8 [20065557.001]
  • [Cites] Genet Med. 2010 Jan;12(1):1-11 [20027112.001]
  • [Cites] Gastrointest Endosc. 2010 Jan;71(1):216-8 [19836738.001]
  • [Cites] Semin Nucl Med. 2010 Mar;40(2):153-63 [20113683.001]
  • [Cites] World J Surg Oncol. 2010;8:14 [20219130.001]
  • [Cites] Eur J Endocrinol. 2010 May;162(5):951-60 [20142367.001]
  • [Cites] Surg Oncol. 2010 Dec;19(4):235-42 [19586767.001]
  • [Cites] J Pediatr. 1994 Jul;125(1):63-6 [8021787.001]
  • [Cites] Br J Cancer. 1994 Nov;70(5):813-8 [7947085.001]
  • [Cites] Br J Cancer. 1994 Nov;70(5):969-72 [7947106.001]
  • [Cites] Ann N Y Acad Sci. 1994 Sep 15;733:425-36 [7978891.001]
  • [Cites] AJR Am J Roentgenol. 1995 Feb;164(2):387-91 [7839976.001]
  • [Cites] Eur J Surg Oncol. 1995 Feb;21(1):78-82 [7851559.001]
  • [Cites] Ann Surg. 1995 Feb;221(2):185-95 [7857146.001]
  • [Cites] J Pediatr. 1995 Mar;126(3):364-7 [7869193.001]
  • [Cites] Br J Cancer. 1995 May;71(5):1070-3 [7734302.001]
  • [Cites] Neurology. 1995 Oct;45(10):1897-902 [7477989.001]
  • [Cites] Ann Surg Oncol. 1995 Nov;2(6):524-9 [8591083.001]
  • [Cites] Neurology. 1996 Jun;46(6):1652-60 [8649565.001]
  • [Cites] J Gastroenterol. 1996 Jun;31(3):460-4 [8726843.001]
  • [Cites] Neurosurgery. 1996 Jun;38(6):1114-8; discussion 1118-9 [8727140.001]
  • [Cites] Gastroenterology. 1997 Feb;112(2):583-90 [9024313.001]
  • [Cites] Ann Neurol. 1997 Feb;41(2):143-9 [9029062.001]
  • [Cites] Surg Today. 1997;27(1):57-9 [9035301.001]
  • [Cites] Arch Pathol Lab Med. 1997 Feb;121(2):139-43 [9126041.001]
  • [Cites] Am J Med Genet. 1997 May 16;70(2):138-43 [9128932.001]
  • [Cites] Arch Dis Child. 1997 Mar;76(3):259-63 [9135269.001]
  • [Cites] Cancer. 1997 Jun 1;79(11):2125-31 [9179058.001]
  • [Cites] Neuroradiology. 1997 Sep;39(9):642-53 [9335063.001]
  • [Cites] Science. 1998 Jan 23;279(5350):577-80 [9438854.001]
  • [Cites] Am J Pathol. 1998 May;152(5):1259-69 [9588894.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2191-203 [9610699.001]
  • [Cites] Arch Dis Child. 1998 May;78(5):408-12 [9659085.001]
  • [Cites] Leuk Res. 1998 Nov;22(11):1003-7 [9783802.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Sep 1;42(2):351-60 [9788415.001]
  • [Cites] Cancer. 1999 Mar 15;85(6):1241-9 [10189128.001]
  • [Cites] Pediatr Hematol Oncol. 1999 May-Jun;16(3):263-6 [10326226.001]
  • [Cites] Nihon Geka Hokan. 1998 Mar 1;67(1):3-9 [10401230.001]
  • [Cites] Am J Med Genet. 1999 Mar 26;89(1):38-44 [10469435.001]
  • [Cites] Radiographics. 1999 Sep-Oct;19(5):1253-80 [10489179.001]
  • [Cites] J Urol. 1999 Nov;162(5):1582-6 [10524872.001]
  • [Cites] Acta Psychiatr Neurol Scand Suppl. 1951;71:1-239 [14877597.001]
  • [Cites] AMA Arch Surg. 1952 Jun;64(6):813-27 [14923105.001]
  • [Cites] Ann Intern Med. 1964 Dec;61:1142-3 [14233837.001]
  • [Cites] J Neurooncol. 2004 Aug-Sep;69(1-3):335-49 [15527099.001]
  • [Cites] Curr Hypertens Rep. 2004 Dec;6(6):477-84 [15527694.001]
  • [Cites] Cancer. 1963 Aug;16:1015-27 [14050005.001]
  • [Cites] Neurology. 2004 Nov 23;63(10):1944-6 [15557519.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Jan 1;156(1):86-8 [15588864.001]
  • [Cites] Ann Oncol. 2005 Apr;16(4):566-78 [15781488.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2618-28 [15728225.001]
  • [Cites] J Gastroenterol Hepatol. 2005 May;20(5):676-81 [15853978.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1717-51 [15887161.001]
  • [Cites] Am J Surg. 2003 Jan;185(1):86-7 [12531453.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):1084-92 [12569610.001]
  • [Cites] Am J Hum Genet. 2003 May;72(5):1288-92 [12660952.001]
  • [Cites] Surg Today. 2003;33(5):323-7 [12734724.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):807-12 [12788189.001]
  • [Cites] J Med Genet. 2003 Jun;40(6):e82 [12807981.001]
  • [Cites] Pediatr Neurol. 2003 Apr;28(4):262-70 [12849878.001]
  • [Cites] J Child Neurol. 2003 Jul;18(7):471-8 [12940652.001]
  • [Cites] Am J Med Genet A. 2003 Oct 1;122A(2):95-9 [12955759.001]
  • [Cites] Br J Cancer. 2006 Jul 17;95(2):233-8 [16786042.001]
  • [Cites] Radiol Med. 2006 Aug;111(5):661-73 [16791465.001]
  • [Cites] AJR Am J Roentgenol. 2006 Aug;187(2):W233-4 [16861519.001]
  • [Cites] Dig Dis Sci. 2006 Jun;51(6):1043-6 [16865565.001]
  • [Cites] Am Fam Physician. 2006 Aug 1;74(3):429-34 [16913162.001]
  • [Cites] J AAPOS. 2006 Aug;10(4):307-11 [16935228.001]
  • [Cites] Cancer. 2006 Sep 1;107(5):1065-74 [16881077.001]
  • [Cites] J Clin Invest. 2006 Sep;116(9):2378-84 [16906226.001]
  • [Cites] Eye (Lond). 2006 Oct;20(10):1149-64 [17019413.001]
  • [Cites] Ophthalmology. 2004 Mar;111(3):568-77 [15019338.001]
  • [Cites] Melanoma Res. 2004 Apr;14(2):159-63 [15057048.001]
  • [Cites] J Pediatr. 2004 May;144(5):666-8 [15127010.001]
  • [Cites] Am J Med Genet A. 2004 Jun 15;127A(3):224-9 [15150770.001]
  • [Cites] Yonsei Med J. 2004 Jun 30;45(3):564-7 [15227750.001]
  • [Cites] Minerva Endocrinol. 2004 Mar;29(1):19-24 [15258554.001]
  • [Cites] Clin Orthop Relat Res. 2004 Sep;(426):69-73 [15346054.001]
  • [Cites] J Clin Oncol. 2004 Sep 15;22(18):3813-25 [15365079.001]
  • [Cites] Arch Neurol. 1966 May;14(5):467-75 [4957904.001]
  • [Cites] Ann Surg. 1970 Mar;171(3):419-28 [5416584.001]
  • [Cites] Br J Ophthalmol. 1969 Dec;53(12):793-8 [5386369.001]
  • [Cites] Am J Surg. 1971 Feb;121(2):195-205 [4322277.001]
  • [Cites] Ann Surg. 1972 Jan;175(1):86-104 [4621893.001]
  • [Cites] Br J Surg. 1972 Apr;59(4):322-3 [4623189.001]
  • [Cites] Cancer. 1973 Jan;31(1):184-90 [4683036.001]
  • [Cites] Cancer. 1977 Jun;39(6):2550-5 [194668.001]
  • [Cites] Cancer. 1977 Mar;39(3):1264-6 [410497.001]
  • [Cites] J Pediatr. 1978 Jun;92(6):925-9 [96239.001]
  • [Cites] Neurosurgery. 1979 Jun;4(6):524-8 [113690.001]
  • [Cites] Cancer. 1981 May 15;47(10):2503-9 [6791802.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1981;392(1):105-9 [6792771.001]
  • [Cites] Adv Neurol. 1981;29:33-56 [6798842.001]
  • [Cites] J Surg Oncol. 1984 Apr;25(4):268-72 [6425563.001]
  • [Cites] Ophthalmology. 1984 Aug;91(8):929-35 [6436764.001]
  • [Cites] J Clin Oncol. 1985 Jan;3(1):117-20 [3917492.001]
  • [Cites] J Tenn Med Assoc. 1985 Mar;78(3):138-40 [3920445.001]
  • [Cites] Cancer. 1986 Mar 15;57(6):1225-9 [3080222.001]
  • [Cites] Cancer. 1986 May 15;57(10):2006-21 [3082508.001]
  • [Cites] Cancer Genet Cytogenet. 1986 Apr 15;21(4):347-54 [3082511.001]
  • [Cites] N Engl J Med. 1986 Apr 17;314(16):1010-5 [3083258.001]
  • [Cites] Am J Surg Pathol. 1986 May;10(5):348-57 [2422964.001]
  • [Cites] Cancer J. 2003 Mar-Apr;9(2):72-81 [12784872.001]
  • [Cites] Cancer. 1986 Jul 15;58(2 Suppl):598-602 [3719551.001]
  • [Cites] Am J Med. 1987 Feb;82(2):384-5 [3101498.001]
  • [Cites] Blood. 1987 Apr;69(4):1237-41 [3103719.001]
  • [Cites] J Clin Oncol. 1987 Apr;5(4):601-12 [3559651.001]
  • [Cites] Ann Intern Med. 1987 May;106(5):772 [3105377.001]
  • [Cites] Nature. 1987 Jun 4-10;327(6121):430-2 [3295562.001]
  • [Cites] Gut. 1987 Sep;28(9):1173-6 [3119436.001]
  • [Cites] Int J Cancer. 1988 Jan 15;41(1):59-64 [3275590.001]
  • [Cites] J Neurosurg. 1988 Jan;68(1):85-98 [3275755.001]
  • [Cites] Am J Hum Genet. 1988 Feb;42(2):284-9 [3124613.001]
  • [Cites] Gut. 1988 Jan;29(1):134 [3125091.001]
  • [Cites] Q J Med. 1987 Sep;64(245):769-82 [2897130.001]
  • [Cites] Gut. 1988 Apr;29(4):553 [3131195.001]
  • [Cites] Oncogene. 1987;1(4):409-13 [3330783.001]
  • [Cites] J Gastrointest Surg. 2003 Sep-Oct;7(6):773-6 [13129555.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Mar;85(5):1629-33 [3278322.001]
  • [Cites] Nucl Med Commun. 2006 Jul;27(7):583-7 [16794519.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8573-7 [14695164.001]
  • [Cites] Hum Mutat. 2004 Feb;23(2):134-46 [14722917.001]
  • [Cites] Am J Med Genet A. 2004 Feb 15;125A(1):94-6 [14755474.001]
  • [Cites] Breast. 2004 Feb;13(1):77-9 [14759722.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):479-91 [14764749.001]
  • [Cites] Am J Ophthalmol. 2004 Mar;137(3):407-14 [15013861.001]
  • [Cites] Cell. 1992 Apr 17;69(2):275-81 [1568247.001]
  • [Cites] Am J Gastroenterol. 1993 Jul;88(7):1124-5 [8317420.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):856-69 [8334640.001]
  • [Cites] Am J Surg Pathol. 1993 Aug;17(8):837-41 [8338194.001]
  • [Cites] Cancer. 1993 Nov 1;72(9):2746-54 [8402499.001]
  • [Cites] Med Pediatr Oncol. 1994;22(2):78-83 [8259105.001]
  • [Cites] N Engl J Med. 1994 Mar 3;330(9):597-601 [8302341.001]
  • [Cites] J Surg Oncol. 1994 Feb;55(2):100-3 [8121181.001]
  • [Cites] Cancer. 1994 Mar 15;73(6):1580-8 [8156484.001]
  • [Cites] Br J Neurosurg. 2003 Aug;17(4):327-35 [14579898.001]
  • [Cites] Strahlenther Onkol. 2003 Sep;179(9):585-97 [14628124.001]
  • [Cites] N Engl J Med. 1992 Jun 25;326(26):1721-6 [1317506.001]
  • [Cites] Cancer. 1993 Feb 15;71(4):1247-53 [8435801.001]
  • [Cites] J Comput Assist Tomogr. 1999 Nov-Dec;23(6):994-1003 [10589584.001]
  • [Cites] Science. 1999 Dec 10;286(5447):2176-9 [10591653.001]
  • [Cites] Am J Epidemiol. 2000 Jan 1;151(1):33-40 [10625171.001]
  • [Cites] Jpn J Cancer Res. 1999 Dec;90(12):1321-8 [10665649.001]
  • [Cites] Otolaryngol Head Neck Surg. 2000 May;122(5):667-72 [10793343.001]
  • [Cites] Acta Neuropathol. 2000 May;99(5):563-70 [10805102.001]
  • [Cites] Am J Med Genet. 2000 Aug 28;93(5):388-92 [10951462.001]
  • [Cites] Arch Intern Med. 2000 Sep 11;160(16):2521-4 [10979065.001]
  • [Cites] Histol Histopathol. 2000 Oct;15(4):1293-301 [11005253.001]
  • [Cites] Eur J Pediatr. 2000 Sep;159(9):692-6 [11014471.001]
  • [Cites] Genet Epidemiol. 2000 Dec;19(4):429-39 [11108651.001]
  • [Cites] Ann Intern Med. 2001 Feb 20;134(4):315-29 [11182843.001]
  • [Cites] Br J Radiol. 2001 Jan;74(877):24-31 [11227773.001]
  • [Cites] J Intern Med. 2001 Mar;249(3):247-51 [11285044.001]
  • [Cites] Am J Ophthalmol. 2001 Apr;131(4):442-5 [11292406.001]
  • [Cites] Arch Ophthalmol. 2001 Apr;119(4):516-29 [11296017.001]
  • [Cites] Neurology. 2001 Apr 10;56(7):827-9 [11294917.001]
  • [Cites] Am J Hum Genet. 2001 May;68(5):1110-8 [11283797.001]
  • [Cites] J Neuroophthalmol. 2001 Mar;21(1):1-7 [11315972.001]
  • [Cites] Chir Ital. 2001 Jan-Feb;53(2):243-6 [11396074.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3091-102 [11408506.001]
  • [Cites] Blood. 2001 Sep 1;98(5):1365-73 [11520784.001]
  • [Cites] J Clin Gastroenterol. 2001 Nov-Dec;33(5):415-7 [11606861.001]
  • [Cites] Mod Pathol. 2001 Nov;14(11):1169-74 [11706080.001]
  • [Cites] AJNR Am J Neuroradiol. 2001 Nov-Dec;22(10):1963-9 [11733333.001]
  • [Cites] Cancer Res. 2002 Mar 1;62(5):1573-7 [11894862.001]
  • [Cites] JAMA. 2002 Mar 20;287(11):1427-34 [11903030.001]
  • [Cites] J Gastroenterol. 2002;37(3):215-9 [11931536.001]
  • [Cites] Am J Pathol. 2002 May;160(5):1567-72 [12000708.001]
  • [Cites] J Med Genet. 2002 May;39(5):311-4 [12011145.001]
  • [Cites] Med Pediatr Oncol. 2002 Jun;38(6):449 [11984810.001]
  • [Cites] J Clin Oncol. 2002 Jun 1;20(11):2672-9 [12039929.001]
  • [Cites] Cancer Cell. 2002 Apr;1(3):269-77 [12086863.001]
  • [Cites] Arch Dis Child. 2002 Jul;87(1):65-70 [12089128.001]
  • [Cites] Pediatr Neurosurg. 2002 Sep;37(3):122-36 [12187057.001]
  • [Cites] Gynecol Oncol. 2002 Sep;86(3):375-8 [12217765.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5551-8 [12359767.001]
  • [Cites] Ann N Y Acad Sci. 2002 Sep;970:170-6 [12381552.001]
  • [Cites] Arch Dis Child. 2002 Nov;87(5):444-5 [12390929.001]
  • [Cites] J Child Neurol. 2002 Aug;17(8):573-7; discussion 602-4, 646-51 [12403555.001]
  • [Cites] Brain. 2003 Jan;126(Pt 1):152-60 [12477702.001]
  • [Cites] J Gastroenterol. 2002;37(11):947-53 [12483251.001]
  • (PMID = 22240541.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neurofibromin 1
  • [Other-IDs] NLM/ PMC3267808
  •  go-up   go-down






Advertisement